What is Solid Biosciences Inc.'s earnings per share (EPS)?

Solid Biosciences Inc. (SLDB) reported diluted earnings per share of -$1.99 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Solid Biosciences Inc. (SLDB) Financials

SLDB

FY2025 annual

Net Income -$174.3M -39.8% YoY

EPS (Diluted) -$1.99 YoY not available

Free Cash Flow -$157.4M -56.4% YoY

Operating Cash Flow -$156.3M -56.3% YoY

Market Cap $932.9M as of Sep 11, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.5x on $374.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLDB SEC filings page.

This page shows Solid Biosciences Inc. (SLDB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SLDB FY2025 2026-08-30

Development spending is accelerating while operations remain cash-consuming, making external financing the dominant business mechanic.

FY2025 research and development was $140M against capital expenditures of $1.2M, making investment primarily expense-funded rather than asset-building. Operating cash flow of -$156M nearly matched free cash flow of -$157M, so cash needs are driven mainly by ongoing operations rather than large physical reinvestment.

The company raised $194M through financing in FY2025 versus operating cash outflow of $156M; external funding, rather than operations, was the larger cash source for the year. The reported liquidity measure stood at 14.4 months of the latest annual operating outflow, which is a balance-to-outflow comparison rather than evidence of operating self-funding.

The balance sheet remains more equity-funded than liability-funded, with FY2025 liabilities of $52.5M versus equity of $180M. A 6.1x current ratio and 0.3x debt-to-equity ratio indicate short-term financial flexibility, while shares outstanding increased from 37.8M in FY2023 to 98.4M in FY2025, showing how financing has increasingly involved equity issuance.

Financial Health Signals

Financial health score not available

Solid Biosciences Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Solid Biosciences Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Solid Biosciences Inc. reported a net loss of $174.3M while operations used $156.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Solid Biosciences Inc. reported an operating loss of $179.2M against $203K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$57.0M

YoY-38.0%

QoQ-0.1%

Solid Biosciences Inc.'s EBITDA was -$57.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 38.0% from the same quarter a year earlier. Against the prior quarter it is down 0.1%.

Net Income

-$54.8M

YoY-38.8%

QoQ+3.4%

Solid Biosciences Inc. reported -$54.8M in net income in Q2 2026. This represents a decrease of 38.8% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.

EPS (Diluted)

-$0.38

QoQ+26.9%

Solid Biosciences Inc. earned -$0.38 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 26.9%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$52.7M

YoY-39.6%

QoQ-11.3%

Solid Biosciences Inc. recorded an outflow of $52.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 39.6% from the same quarter a year earlier. Against the prior quarter it is down 11.3%.

Cash & Debt

$159.4M

YoY+14.7%

QoQ-46.3%

5Y CAGR-4.5%

Solid Biosciences Inc. held $159.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

107M

QoQ+8.9%

5Y CAGR-0.6%

Solid Biosciences Inc. had 107M shares outstanding in Q2 2026. Against the prior quarter it is up 8.9%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-14.6%

YoY+0.6pp

QoQ+0.5pp

Solid Biosciences Inc.'s ROE was -14.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$44.3M

YoY+36.6%

QoQ-4.1%

Solid Biosciences Inc. invested $44.3M in research and development in Q2 2026. This represents an increase of 36.6% from the same quarter a year earlier. Against the prior quarter it is down 4.1%.

Capital Expenditures

$150K

YoY-60.2%

QoQ-9.1%

5Y CAGR-15.5%

Solid Biosciences Inc. invested $150K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 60.2% from the same quarter a year earlier. Against the prior quarter it is down 9.1%.

Share Buybacks

Not reported for Q2 2026.

SLDB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SLDB quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	N/A	N/A	N/A	N/A	$8.1M-40.6%	$13.6M	$0	$0	$0	$0	$0
R&D Expenses	N/A	$140.3M+45.5%	$96.4M+25.9%	$76.6M-2.4%	$78.4M+33.5%	$58.7M-9.5%	$64.9M-31.5%	$94.7M+63.4%	$58.0M+45.3%	$39.9M+98.4%	$20.1M
SG&A Expenses	N/A	$38.9M+16.8%	$33.3M+20.0%	$27.8M-4.1%	$28.9M+6.7%	$27.1M+25.7%	$21.6M-12.2%	$24.6M+38.7%	$17.7M+18.5%	$15.0M+173.8%	$5.5M
Operating Income	N/A	-$179.2M-38.1%	-$129.7M-24.4%	-$104.3M+2.1%	-$106.5M-47.3%	-$72.3M+18.3%	-$88.4M+25.9%	-$119.3M-57.6%	-$75.7M-38.0%	-$54.9M-114.5%	-$25.6M
EBITDA	N/A	-$177.6M-39.5%	-$127.3M-25.2%	-$101.7M+2.3%	-$104.0M-50.2%	-$69.3M+18.0%	-$84.5M+27.5%	-$116.5M-57.2%	-$74.1M-36.2%	-$54.4M-113.2%	-$25.5M
Interest Expense	N/A	-$203K-159.7%	$340K-22.7%	$440K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A
Net Income	N/A	-$174.3M-39.8%	-$124.7M-29.9%	-$96.0M-11.7%	-$86.0M-19.1%	-$72.2M+18.2%	-$88.3M+24.7%	-$117.2M-56.7%	-$74.8M-43.5%	-$52.1M-142.0%	-$21.5M
EPS (Basic)	N/A	-$1.99+35.0%	-$3.06+36.6%	-$4.83+52.2%	-$10.10+0.4%	-$10.14+60.2%	-$25.50	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.91	-$1.99	-$3.06	-$4.83	-$10.10	-$10.14	-$25.50	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	88M	41M	20M	9M	7M	3M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$44.3M+36.6%	$46.1M+49.3%	N/A	$38.9M+42.2%	$32.4M+66.6%	$30.9M+63.8%	N/A	$27.3M+63.6%
SG&A Expenses	$13.1M+41.4%	$11.2M+22.2%	N/A	$9.2M+17.1%	$9.3M+11.4%	$9.1M+14.4%	N/A	$7.9M+22.5%
Operating Income	-$57.4M-37.6%	-$57.3M-43.1%	N/A	-$48.1M-36.6%	-$41.7M-50.0%	-$40.1M-49.1%	N/A	-$35.2M-52.2%
EBITDA	-$57.0M-38.0%	-$56.9M-43.6%	N/A	-$47.7M-37.1%	-$41.3M-55.6%	-$39.6M-49.4%	N/A	-$34.8M-54.4%
Interest Expense	N/A	N/A	N/A	-$336K-509.8%	$60K-31.8%	$68K-28.4%	N/A	$82K-22.6%
Net Income	-$54.8M-38.8%	-$56.7M-44.4%	N/A	-$45.8M-39.9%	-$39.5M-57.5%	-$39.3M-61.6%	N/A	-$32.7M-56.0%
EPS (Basic)	-$0.38+9.5%	-$0.52+11.9%	-$0.53+48.0%	-$0.48+39.2%	-$0.42+31.1%	-$0.59+7.8%	-$1.02-2.0%	-$0.79+24.8%
EPS (Diluted)	-$0.38	-$0.52	-$0.53+48.0%	-$0.48	-$0.42	-$0.59	-$1.02	-$0.79
Diluted Shares (Avg)	144M	110M	N/A	94M	94M	66M	N/A	41M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

SLDB Balance Sheet

SLDB quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$232.5M+23.3%	$188.7M+14.4%	$164.9M-36.6%	$260.3M+12.0%	$232.4M+35.8%	$171.2M+65.4%	$103.5M-25.9%	$139.6M+83.2%	$76.2M	N/A
Current Assets	$205.5M+30.6%	$157.3M+21.2%	$129.7M-40.9%	$219.6M-1.3%	$222.6M+40.1%	$158.9M+84.1%	$86.3M-32.9%	$128.6M+82.1%	$70.7M	N/A
Cash & Equivalents	$59.9M-25.3%	$80.2M+8.4%	$74.0M-52.4%	$155.4M+30.4%	$119.1M-23.0%	$154.7M+103.5%	$76.0M-12.0%	$86.4M+65.8%	$52.1M+578.3%	$7.7M
Short-Term Investments	$128.0M+86.3%	$68.7M+38.4%	$49.6M-14.9%	$58.3M-34.2%	$88.6M	$0-100.0%	$7.5M-79.3%	$36.1M+112.2%	$17.0M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$52.5M+2.2%	$51.4M+33.7%	$38.5M-20.8%	$48.6M+101.0%	$24.2M-38.2%	$39.1M+66.9%	$23.4M+62.5%	$14.4M-89.4%	$135.4M	N/A
Current Liabilities	$33.5M+10.6%	$30.3M+108.4%	$14.5M-35.5%	$22.5M-4.6%	$23.6M-3.6%	$24.5M+33.9%	$18.3M+46.4%	$12.5M+10.7%	$11.3M	N/A
Non-Current Liabilities	$19.1M-9.9%	$21.2M-11.6%	$23.9M-8.2%	$26.1M+4491.2%	$568K-96.1%	$14.6M+183.7%	$5.1M+166.3%	$1.9M-98.4%	$124.2M	N/A
Total Equity	$180.0M+31.2%	$137.2M+8.5%	$126.5M-40.2%	$211.7M+1.7%	$208.2M+57.6%	$132.1M+65.0%	$80.0M-36.1%	$125.2M+311.3%	-$59.3M-56.4%	-$37.9M
Retained Earnings	-$957.8M-22.3%	-$783.5M-18.9%	-$658.8M-17.1%	-$562.7M-18.0%	-$476.8M-17.8%	-$404.6M-27.9%	-$316.3M-58.9%	-$199.1M-60.2%	-$124.3M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$420.6M+36.4%	$422.9M+23.0%	$232.5M+23.3%	$273.9M+29.3%	$308.3M+33.5%	$343.9M+38.3%	$188.7M+14.4%	$211.8M+14.7%
Current Assets	$395.1M+41.8%	$396.8M+26.6%	$205.5M+30.6%	$244.9M+36.4%	$278.6M+41.0%	$313.4M+46.3%	$157.3M+21.2%	$179.5M+21.0%
Cash & Equivalents	$159.4M+14.7%	$297.1M+41.1%	$59.9M-25.3%	$61.4M-4.7%	$138.9M+44.9%	$210.6M+79.1%	$80.2M+8.4%	$64.4M+31.3%
Short-Term Investments	$218.3M+69.0%	$83.6M-13.2%	$128.0M+86.3%	$174.8M+63.8%	$129.2M+36.8%	$96.3M+8.8%	$68.7M+38.4%	$106.7M+13.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$46.5M-7.0%	$48.8M-1.4%	$52.5M+2.2%	$56.0M+24.9%	$50.0M+32.5%	$49.4M+30.2%	$51.4M+33.7%	$44.8M+11.0%
Current Liabilities	$28.6M-4.2%	$30.3M+5.2%	$33.5M+10.6%	$36.3M+59.0%	$29.8M+103.2%	$28.8M+100.7%	$30.3M+108.4%	$22.9M+44.5%
Non-Current Liabilities	$17.9M-11.1%	$18.5M-10.6%	$19.1M-9.9%	$19.6M-10.6%	$20.2M-12.6%	$20.7M-12.5%	$21.2M-11.6%	$21.9M-10.6%
Total Equity	$374.1M+44.8%	$374.1M+27.1%	$180.0M+31.2%	$217.9M+30.5%	$258.3M+33.7%	$294.5M+39.7%	$137.2M+8.5%	$167.0M+15.7%
Retained Earnings	-$1.1B-24.0%	-$1.0B-23.3%	-$957.8M-22.3%	-$908.0M-22.6%	-$862.2M-21.8%	-$822.7M-20.4%	-$783.5M-18.9%	-$740.9M-16.0%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

SLDB Cash Flow Statement

SLDB quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$186.8M	-$156.3M-56.3%	-$100.0M-6.2%	-$94.2M+3.9%	-$98.0M-26.0%	-$77.8M-37.4%	-$56.6M+39.0%	-$92.7M-32.1%	-$70.2M-62.4%	-$43.2M-114.8%	-$20.1M
Depreciation & Amortization	N/A	$1.6M-33.4%	$2.5M-4.9%	$2.6M+7.2%	$2.4M-18.8%	$3.0M-24.4%	$3.9M+38.9%	$2.8M+80.3%	$1.6M+249.6%	$448K+700.0%	$56K
Stock-Based Compensation	N/A	$16.9M+60.8%	$10.5M+38.0%	$7.6M+1.2%	$7.5M-43.6%	$13.4M+15.0%	$11.6M-18.1%	$14.2M+138.6%	$6.0M+11.7%	$5.3M+262.6%	$1.5M
Capital Expenditures	$965K	$1.2M+76.3%	$654K-56.8%	$1.5M-49.8%	$3.0M+135.4%	$1.3M+42.5%	$899K-79.5%	$4.4M-43.6%	$7.8M+241.7%	$2.3M+480.6%	$392K
Free Cash Flow	-$187.8M	-$157.4M-56.4%	-$100.7M-5.2%	-$95.7M+5.2%	-$101.0M-27.8%	-$79.0M-37.5%	-$57.5M+40.8%	-$97.1M-24.5%	-$78.0M-71.4%	-$45.5M-121.8%	-$20.5M
Investing Cash Flow	-$87.1M	-$58.5M-263.4%	-$16.1M-266.0%	$9.7M-83.6%	$59.2M+164.9%	-$91.1M-1480.1%	$6.6M-73.1%	$24.5M+191.6%	-$26.8M-356.1%	$10.4M+357.8%	-$4.1M
Financing Cash Flow	$293.8M	$194.4M+58.8%	$122.4M+3821.7%	$3.1M-95.8%	$74.8M-44.6%	$135.0M+4.9%	$128.7M+122.4%	$57.9M-56.0%	$131.5M+70.6%	$77.1M+2153.7%	$3.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$52.6M-40.6%	-$47.2M-48.3%	-$53.6M-80.7%	-$33.5M-41.2%	-$37.4M-74.3%	-$31.9M-26.4%	-$29.6M-42.4%	-$23.7M-32.5%
Depreciation & Amortization	$391K+1.3%	$395K-2.9%	$467K-4.3%	$376K-7.2%	$386K-68.7%	$407K+24.5%	$488K	$405K-31.1%
Stock-Based Compensation	$5.6M+78.6%	$5.2M+54.2%	N/A	$3.9M+31.2%	$3.1M+50.3%	$3.3M+107.4%	N/A	$3.0M+84.3%
Capital Expenditures	$150K-60.2%	$165K+31.0%	$565K+177.0%	$85K+466.7%	$377K+31.8%	$126K-15.4%	$204K+126.7%	$15K-96.1%
Free Cash Flow	-$52.7M-39.6%	-$47.4M-48.2%	-$54.1M-81.3%	-$33.6M-41.5%	-$37.8M-73.7%	-$32.0M-26.2%	-$29.8M-42.7%	-$23.7M-29.8%
Investing Cash Flow	-$133.6M-308.1%	$44.8M+263.0%	$47.0M+21.9%	-$45.3M-312.1%	-$32.7M-532.4%	-$27.5M+28.6%	$38.6M-14.9%	-$11.0M+55.4%
Financing Cash Flow	$48.5M+3127.5%	$239.0M+26.0%	$5.1M-25.9%	$1.2M-63.9%	-$1.6M-132.0%	$189.7M+76.9%	$6.9M+1274.3%	$3.3M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SLDB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SLDB quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Margin	N/A	N/A	N/A	-1315.2%	-530.5%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-1062.3%	-530.0%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-96.8%-6.0pp	-90.9%-14.9pp	-75.9%-35.3pp	-40.6%-5.9pp	-34.7%+32.2pp	-66.8%+79.6pp	-146.4%-86.7pp	-59.8%	N/A	N/A
Return on Assets	-75.0%-8.9pp	-66.1%-7.9pp	-58.2%-25.2pp	-33.0%-2.0pp	-31.1%+20.5pp	-51.6%+61.7pp	-113.3%-59.7pp	-53.6%+14.8pp	-68.4%	N/A
Current Ratio	6.14+0.9x	5.20-3.7x	8.94-0.8x	9.76+0.3x	9.43+2.9x	6.49+1.8x	4.72-5.6x	10.31+4.0x	6.27	N/A
Debt-to-Equity	0.29-0.1x	0.37+0.1x	0.30+0.1x	0.23+0.1x	0.12-0.2x	0.300.0x	0.29+0.2x	0.12	N/A	N/A
Asset Turnover	N/A	N/A	N/A	0.030.0x	0.06+0.1x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A
FCF Margin	N/A	N/A	N/A	-1247.7%	-580.4%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-14.6%+0.6pp	-15.2%-1.8pp	N/A	-21.0%-1.4pp	-15.3%-2.3pp	-13.3%-1.8pp	N/A	-19.6%-5.1pp
Return on Assets	-13.0%-0.2pp	-13.4%-2.0pp	N/A	-16.7%-1.3pp	-12.8%-2.0pp	-11.4%-1.7pp	N/A	-15.4%-4.1pp
Current Ratio	13.82+4.5x	13.10+2.2x	6.14+0.9x	6.74-1.1x	9.34-4.1x	10.89-4.0x	5.20-3.7x	7.85-1.5x
Debt-to-Equity	0.12-0.1x	0.130.0x	0.29-0.1x	0.260.0x	0.190.0x	0.170.0x	0.37+0.1x	0.270.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Solid Biosciences Inc. SLDB	FY2025	N/A	-$174.3M	N/A	$932.9M	—
Aura Biosciences, Inc. AURA	FY2025	N/A	-$106.2M	N/A	$724.9M	—
Lexicon Pharmaceuticals Inc LXRX	FY2025	$49.8M	-$50.3M	N/A	$898.8M	64/100
Fulcrum Therapeutics FULC	FY2025	$0	-$74.9M	N/A	$289.9M	—
Diamedica Therapeutics Inc DMAC	FY2025	N/A	-$32.8M	N/A	$348.9M	—
Alumis Inc ALMS	FY2025	$24.1M	-$243.3M	N/A	$1.3B	37/100

Where Solid Biosciences Inc. Ranks

Frequently Asked Questions

Is Solid Biosciences Inc. profitable?

No, Solid Biosciences Inc. (SLDB) reported a net income of -$174.3M in fiscal year 2025.

What is Solid Biosciences Inc.'s EBITDA?

Solid Biosciences Inc. (SLDB) had EBITDA of -$177.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Solid Biosciences Inc.'s return on equity (ROE)?

Solid Biosciences Inc. (SLDB) has a return on equity of -96.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Solid Biosciences Inc.'s free cash flow?

Solid Biosciences Inc. (SLDB) recorded an outflow of $157.4M in free cash flow during fiscal year 2025. This represents a -56.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Solid Biosciences Inc.'s operating cash flow?

Solid Biosciences Inc. (SLDB) recorded an outflow of $156.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Solid Biosciences Inc.'s total assets?

Solid Biosciences Inc. (SLDB) had $232.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Solid Biosciences Inc.'s capital expenditures?

Solid Biosciences Inc. (SLDB) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Solid Biosciences Inc. spend on research and development?

Solid Biosciences Inc. (SLDB) invested $140.3M in research and development during fiscal year 2025.

How many shares does Solid Biosciences Inc. have outstanding?

Solid Biosciences Inc. (SLDB) had 98M shares outstanding as of fiscal year 2025.

What is Solid Biosciences Inc.'s current ratio?

Solid Biosciences Inc. (SLDB) had a current ratio of 6.14 as of fiscal year 2025, which is generally considered healthy.

What is Solid Biosciences Inc.'s debt-to-equity ratio?

Solid Biosciences Inc. (SLDB) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Solid Biosciences Inc.'s return on assets (ROA)?

Solid Biosciences Inc. (SLDB) had a return on assets of -75.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Solid Biosciences Inc.'s P/E ratio?

Solid Biosciences Inc. (SLDB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $932.9M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Solid Biosciences Inc.'s price-to-sales ratio?

Solid Biosciences Inc. (SLDB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $932.9M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Solid Biosciences Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Solid Biosciences Inc. (SLDB) held $187.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $156.3M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Solid Biosciences Inc.'s Piotroski F-Score?

Solid Biosciences Inc. (SLDB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Solid Biosciences Inc.'s earnings high quality?

Solid Biosciences Inc. (SLDB) reported a net loss of $174.3M while operations used $156.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Solid Biosciences Inc. cover its interest payments?

Solid Biosciences Inc. (SLDB) reported an operating loss of $179.2M against $203K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.